2025
Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids
Becker W, Seal K, Nelson D, DeRonne B, Kats A, Morasco B, Frank J, Makris U, Painter J, Allen K, Mixon A, Bohnert A, Reznik T, Hagedorn H, Hammett P, Borsari B, Baxley C, Krebs E, Abelleira A, Adams M, Amundson E, Anicich A, Ankawi B, Arnold S, Aryal A, Atkins D, Atkinson T, Backe K, Bair M, Bajpai S, Baller K, Bangerter A, Barbosa M, Barnett S, Bartlett S, Bartnik M, Baskin J, Blehm R, Bloechl P, Boening N, Boesch N, Bolander S, Bolf M, Bonchak J, Booth K, Bordanea M, Borowa D, Bowden M, Britnell S, Broderick D, Bronars C, Brooks K, Brown C, Brudvik E, Buchanan K, Buesgens C, Buonora M, Burch R, Burton C, Bhushan S, Butler C, Byerly S, Byrd C, Byrd G, Campbell E, Cariveau D, Carmody S, Carr M, Carr T, Cervone D, Chandler M, Clarke K, Clay M, Coy W, Craine M, Culver D, Cutting A, Dadabayev A, Daly D, Degerstrom R, Denietolis A, DePesa N, Desmet P, Devlin A, Dike D, Diokpa C, Dogra M, Drexler K, Drum-Oden A, Duvall T, Eads F, Edmond S, Eichelsdoerfer E, Ellifritz C, Ellison J, Erwin K, Escobedo C, Feighner L, Feuchs A, Fike A, Finetti T, Franchina L, Freeman J, Frontera R, Galvan R, Garvey C, Gayle S, Givens C, Glenn R, Godwin K, Goldstein M, Gosselin K, Graham S, Grimm K, Gumidyala A, Hagerman C, Hale A, Hall L, Harden J, Hawkins J, Hepton S, Herbst E, Herynk A, Heuermann B, Hidalgo N, Hoffmann J, Holland-deguire C, Hope K, Horowitz D, Huang A, Hudson T, Huffman K, Hunt N, Hyde S, Jacobson K, Jensen A, Johnson E, Jones E, Kaiser B, Kauzlarich K, Kavathekar R, Kerns R, Knutson R, Kross T, Lagisetty P, LaHaie E, Lahidji S, Le G, Lelovic M, Lewis M, Librodo S, Linden E, Lindsay D, Lively-Brindley L, Lorenzo J, Luciani L, Lusk C, Mahal-Lichty J, Maloy P, Manuel J, Mapara P, Marcolivio K, Marcy B, Marek L, Marraffa R, Mason B, McCamish N, McKissack M, Miller E, Moon J, Morris H, Mundt J, Naylor J, Nazario M, Nelson A, Nichols A, Njau E, Noh M, Nolan C, Nolan P, Nugent S, Oakley J, Ofstad H, Okere J, Olney R, Olson J, Ortolan V, Osborne J, Osler B, Packard-Milam M, Palyo S, Patel A, Wiener C, Peter D, Philippe M, Pinsonnault J, Purcell N, Reddy S, Reed J, Rettmann N, Rezaei D, Roberti A, Robinson V, Roca H, Romano E, Rosema T, Rouse R, Rozzero P, Rutks I, Sabet R, Sacra E, Sadowski N, Salameh H, Sandbrink F, Sauve C, Schopmeyer K, Schroeder A, Sculley M, Sellinger J, Sewell K, Seys R, Shah Barman M, Sharpe P, Sides T, Silver K, Siver M, Sloan J, Smith C, Son E, Stevens S, Stoll J, Stoll S, Stoner T, Strand M, Sumner J, Surginer B, Svabek K, Swanson G, Tappainer C, Tat C, Taylor B, Theis A, Thomas L, Thomas G, Tiene K, Udouj R, Ugbo E, Varughese S, Venkatraman S, Viera K, Walker J, Walker J, Wang G, Watson K, Watson E, Westmoreland W, Wilbur E, Williams B, Wolfman A, Woloszyn M, Zanga J, Zuniga S. Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids. JAMA Internal Medicine 2025, 185 PMID: 39960730, PMCID: PMC11833656, DOI: 10.1001/jamainternmed.2024.8361.Peer-Reviewed Original ResearchThis study assessed whether switching chronic pain patients from high-dose opioids to buprenorphine improved pain or reduced opioid use, finding no improvements compared with not offering the switch.Pain Coping Skills Training for Patients Receiving Hemodialysis
Dember L, Hsu J, Mehrotra R, Cavanaugh K, Kalim S, Charytan D, Fischer M, Jhamb M, Johansen K, Becker W, Pellegrino B, Eneanya N, Schrauben S, Pun P, Unruh M, Morasco B, Mehta M, Miyawaki N, Penfield J, Bernardo L, Brintz C, Cheatle M, Doorenbos A, Heapy A, Keefe F, Krebs E, Kuzla N, Nigwekar S, Schmidt R, Steel J, Wetmore J, White D, Kimmel P, Cukor D, Adams M, Almonte-Then S, Amonu C, Anderson L, Argega Leon A, Argyropoulos C, Ashley E, Bajana Meza M, Bansal N, Barbosa M, Barrell T, Bart G, Barton A, Beach S, Beeks L, Belcher J, Berman N, Berry D, Bhatraju E, Bishop N, Blazes C, Busch A, Cameron S, Cardona M, Casilli V, Cazes M, Chacon Palma G, Chalamidas K, Chaudry S, Chen N, Chicos I, Clark C, Collins D, Connelly L, Contreras B, Cosmin A, Crowley S, Dalton C, Dirks J, Donahue S, Dutka P, Dyer V, Edeh O, Edwards D, Edwards D, Ekor K, Esserman D, Falker C, Farkas L, Farrar J, Felson S, Flores Y, Fraticelli Ortiz D, Garcia G, Gear L, Geibel A, Gilmartin C, Goldfarb D, Goldfeld K, Goldstein A, Gong A, Grant C, Grindstaff R, Guajardo E, Guy C, Hamm M, Hammond J, Harris K, Hoffman S, Holden C, Howell H, Ikizler T, Joffe S, Joffe J, Johnson S, Kalam E, Kampman K, Keane C, Kimura G, Kirsch O, Kourany W, Krishnamurthy P, Kubrick P, Lacey P, Landis J, Lash J, Lazlo K, Lee J, Lefler J, Leon Cupe A, Lerner S, Liebschutz J, Lietz P, Linke L, Lockwood M, Luo H, Macina A, McCarthy A, McDaniels K, McLaren S, McNeil D, Meinel M, Mejia V, Mengesha B, Merriman D, Michael W, Mims R, Mishra P, Modersitzki F, Moss A, Mullins C, Munet U, O'Connell K, Okereke U, Olejniczak D, Opeke S, Pacheco-Hernandez M, Pankratz S, Park D, Payne K, Pegues H, Percy S, Pleasant S, Purdy T, Quinn D, Quintana N, Rice K, Robinson G, Roche C, Rodriguez Sosa G, Rudow G, Rudy Q, Rutledge J, Sanchez S, Sands B, Scherer J, Schopp M, Self B, Shallcross A, Silva K, Stallings T, Stauffer C, Steffen A, Stewart T, Stringfellow S, Sullivan L, Torres R, Torres J, Trejo G, Varela D, Vassilieva S, Vilchis H, Villareal D, Walsh J, Ways J, Weidner T, Weimer M, Weiner D, Weisbord S, Wilkie C, Wilkinson M, Williams S, Williams J, Wilson O, Wood V, Yabes J, Zamora G, Zaniga S. Pain Coping Skills Training for Patients Receiving Hemodialysis. JAMA Internal Medicine 2025, 185: 197-207. PMID: 39786400, PMCID: PMC11791705, DOI: 10.1001/jamainternmed.2024.7140.Peer-Reviewed Original ResearchConceptsPain coping skills trainingPain coping skills training groupUsual care groupBrief Pain InventoryUsual carePain interferenceCoping skills trainingCare groupQuality of lifePain catastrophizingPain intensityBPI interferenceOutcomes of pain intensityRandomized clinical trialsSecondary outcomesChronic painSecondary outcomes of pain intensitySkills trainingBPI interference scoreCognitive behavioral interventionProportion of participantsOutpatient dialysis facilitiesClinically meaningful improvementsPain interventionsRandomized clinical trial of patientsA Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States
Houtchens M, Manieri M, Mahlanza T, Pol-Patil J, Klawiter E, Solomon A, Lathi E, Katz J, Ionete C, Morales I, Severson C, Zurawski J, Stankiewicz J, Cabot A, Sadovnick A. A Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States. Neurology Clinical Practice 2025, 15: e200425. PMID: 39810912, PMCID: PMC11727603, DOI: 10.1212/cpj.0000000000200425.Peer-Reviewed Original ResearchDisease-modifying therapiesHigh-risk pregnanciesPregnancy RegistryPregnancy outcomesMultiple sclerosisConception attemptsTreated with disease-modifying therapiesBaseline Expanded Disability Status ScaleAdverse pregnancy outcomesClinical disease activityCourse of MSExpanded Disability Status ScaleLonger-term developmental outcomesYears of postpartumReproductive-age womenAssisted reproductive technologyDisability Status ScalePeripartum complicationsTime of conceptionObstetric complicationsPostpartum exacerbationPostpartum relapseIntrapartum periodDisease activityProportion of participants
2024
Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
Komrokji R, Diez-Campelo M, Chee L, Cluzeau T, DeZern A, Fenaux P, Garcia-Manero G, Giagounidis A, Platzbecker U, Della Porta M, Santini V, Sekeres M, Zeidan A, Buckstein R, Ross M, Jiang Y, Bobba S, Hankin M, Materna C, Graham C, Thamake S, Rovaldi C, Grayson D, Salstrom J. Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS). Blood 2024, 144: 3228.1-3228.1. DOI: 10.1182/blood-2024-200797.Peer-Reviewed Original ResearchDurability of responseMyelodysplastic neoplasmsFollow-up periodTransfusion burdenProportion of participantsAdverse eventsTransfusion independenceIneffective hematopoiesisDouble-blindPlacebo-controlled phase 3 studyAchievement of transfusion independenceMultiple stages of hematopoiesisSafety follow-up periodDouble-blind treatment periodLong-term follow-up periodSeverity of adverse eventsLong-term follow-upErythroid maturation agentLow transfusion burdenSustained hematologic improvementTreatment of transfusion-dependent anemiaPlacebo-controlled studyTransfusion-dependent anemiaPhase 3 studyProgression to AMLSurvodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
Wharton S, le Roux C, Kosiborod M, Platz E, Brueckmann M, Jastreboff A, Hussain S, Pedersen S, Borowska L, Unseld A, Kloer I, Kaplan L, committees and investigators T. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2). Obesity 2024, 33: 67-77. PMID: 39495965, PMCID: PMC11664303, DOI: 10.1002/oby.24184.Peer-Reviewed Original ResearchTreatment of obesityBaseline BMIRandomized phase 3 clinical trialOnce-weekly subcutaneous injectionsPhase 3 clinical trialsBaseline to weekDouble-blind trialObesity-related complicationsBody weight reductionAbsence of T2DSystolic blood pressureLiver fat contentType 2 diabetesMagnetic resonance imagingMeasures of glycemiaSecondary endpointsDosing flexibilityProportion of participantsLifestyle modificationInvestigated glucagonSubcutaneous injectionBlood pressureBody compositionResonance imagingObesityScreening, brief intervention, and referral to treatment for pain management for veterans separating from military service: study protocol of a hybrid type 2 study testing implementation facilitation versus training-as-usual
Sellinger J, Rosen M, Lazar C, Gilstad-Hayden K, Dziura J, Li F, Mattocks K, Weede A, Sullivan-Tibbs M, Rose L, Vassallo G, Manhapra A, Turner A, Vogt D, Woodward E, Hartmann C, Haskell S, Mohammad A, Martino S. Screening, brief intervention, and referral to treatment for pain management for veterans separating from military service: study protocol of a hybrid type 2 study testing implementation facilitation versus training-as-usual. Pain Medicine 2024, 25: s99-s106. PMID: 39514877, DOI: 10.1093/pm/pnae062.Peer-Reviewed Original ResearchConceptsTraining-as-usualImplementation facilitatorsReferral to treatmentCase managementBrief interventionHybrid type 2 effectiveness-implementation trialPain managementImplementation strategiesPrimary implementation outcomeSubstance misuseProportion of participantsPain careUsefulness of screeningVeteran engagementVA sitesImplementation outcomesPragmatic trialPain serviceVeteran participantsCase management systemPain intensityDischarged veteransStudy enrollmentVeteransChronic painPhenotypes of sleep health among adults with chronic heart failure in a randomized controlled trial of cognitive behavioral therapy for insomnia
Jeon S, Conley S, O'Connell M, Wang Z, Redeker N. Phenotypes of sleep health among adults with chronic heart failure in a randomized controlled trial of cognitive behavioral therapy for insomnia. Sleep Health 2024, 10: 705-712. PMID: 39482227, PMCID: PMC11624990, DOI: 10.1016/j.sleh.2024.09.006.Peer-Reviewed Original ResearchEmergency department visitsRandomized controlled trial of cognitive behavioral therapyCognitive behavioral therapyTrial of cognitive behavioral therapyDepartment visitsHealth phenotypesRandomized controlled trialsBehavioral therapyProportion of participantsGeneralized estimating equationsCox proportional hazards modelsProportional hazards modelCircadian quotientLinear mixed modelsLower fatigueGeneralized linear mixed modelsSecondary analysisWalking distanceSleep healthCollected hospitalFunctional performanceSleep phenotypesPoor sleepAdverse healthHeart failure outcomesSafety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial
Allegretti J, Kelly C, Louie T, Fischer M, Hota S, Misra B, Van Hise N, Yen E, Bullock J, Silverman M, Davis I, McGill S, Pardi D, Orenstein R, Grinspan A, El-Nachef N, Feuerstadt P, Borody T, Khanna S, Budree S, Kassam Z. Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial. Gastroenterology 2024, 168: 357-366.e3. PMID: 39366468, DOI: 10.1053/j.gastro.2024.09.030.Peer-Reviewed Original ResearchCDI recurrenceRecurrent Clostridioides difficile infectionClostridioides difficile infectionGroup compared to placeboStandard-of-careWeek 8Preventing recurrent Clostridioides difficile infectionReduce recurrent Clostridioides difficile infectionSafety profile similar to placeboRecurrent C. difficile infectionIncidence of adverse eventsPlacebo-controlled trialPrevention of recurrent C. difficile infectionPhase 2 randomized controlled trialMicrobiome therapeuticsToxin EIADouble-blindEfficacy endpointPCR-based testsDiagnostic modalitiesOral doseDifficile infectionProportion of participantsAdverse eventsPlaceboCombined interventions for the testing and treatment of HIV and schistosomiasis among fishermen in Malawi: a three-arm, cluster-randomised trial
Choko A, Dovel K, Kayuni S, Conserve D, Buttterworth A, Bustinduy A, Stothard J, Kamchedzera W, Mukoka-Thindwa M, Jafali J, MacPherson P, Fielding K, Desmond N, Corbett E. Combined interventions for the testing and treatment of HIV and schistosomiasis among fishermen in Malawi: a three-arm, cluster-randomised trial. The Lancet Global Health 2024, 12: e1673-e1683. PMID: 39304239, PMCID: PMC11420466, DOI: 10.1016/s2214-109x(24)00283-3.Peer-Reviewed Original ResearchConceptsVoluntary male medical circumcisionHIV self-test kitsCluster randomised trialSelf-test kitsPeer educatorsDistribution of HIV self-testing kitsIncrease uptake of ARTSOC groupUptake of antiretroviral therapyThree-armEnhanced standard of careAntiretroviral therapyRisk ratioNational Institute for Health ResearchHard-to-reach communitiesMale medical circumcisionUK National Institute for Health ResearchStandard of careProportion of participantsIntracluster correlation coefficientPE groupComputer-generated random numbersActive schistosomiasisUndiagnosed HIVAntiretroviral therapy initiationMadarosis Among Breast Cancer Survivors
Premji S, Ruddy K, Larson N, Loprinzi C, Dulmage B, Lustberg M, Couch F, Olson J, Cathcart-Rake E. Madarosis Among Breast Cancer Survivors. Clinical Breast Cancer 2024, 24: e757-e763. PMID: 39366882, PMCID: PMC11606755, DOI: 10.1016/j.clbc.2024.09.002.Peer-Reviewed Original ResearchBreast cancer survivorsMayo Clinic Breast Disease RegistryQuality of lifeCancer survivorsProportion of breast cancer survivorsLower mental health scoresCohort studyChemotherapy recipientsMental health scoresDiagnosis of breast cancerLongitudinal cohort studyCancer-directed therapyProportion of participantsHealth scoresConsenting participantsDistressing symptomsAge of survivorsDisease RegistryMedian age of survivorsEyelash lossSurvivorsBreast cancerParticipantsEyebrow lossBreastEffect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy Results From SEQUOIA-HCM
Sherrod C, Saberi S, Nassif M, Claggett B, Coats C, Garcia-Pavia P, Januzzi J, Lewis G, Ma C, Maron M, Miao Z, Olivotto I, Veselka J, Butzner M, Jacoby D, Heitner S, Kupfer S, Malik F, Meng L, Wohltman A, Spertus J. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy Results From SEQUOIA-HCM. Journal Of The American College Of Cardiology 2024, 84: 1773-1785. PMID: 39217569, DOI: 10.1016/j.jacc.2024.08.014.Peer-Reviewed Original ResearchKCCQ overall summary scoresKansas City Cardiomyopathy QuestionnaireObstructive hypertrophic cardiomyopathyHealth statusQuality of lifePatient-reported health statusParticipants' health statusHealth status outcomesHypertrophic cardiomyopathyHealth status benefitsHealth status improvementPatients' health statusClinically important changeProportion of participantsSymptoms of fatigueSymptomatic obstructive hypertrophic cardiomyopathyStatus outcomesSummary scoreImprove healthCardiac myosin inhibitorProportion of patientsBaseline scoresImportant changesShortness of breathStatus improvementLearning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial
Song J, Wang X, Wang B, Ge Y, Bi L, Jing F, Jin H, Li T, Gu B, Wang L, Hao J, Zhao Y, Liu J, Zhang H, Li X, Li J, Ma W, Wang J, Normand S, Herrin J, Armitage J, Krumholz H, Zheng X. Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial. The BMJ 2024, 386: e079143. PMID: 39043397, PMCID: PMC11265211, DOI: 10.1136/bmj-2023-079143.Peer-Reviewed Original ResearchConceptsClinical decision support systemsPrimary care practicesElectronic health recordsIntervention groupSystolic blood pressurePrimary careCare practicesBlood pressure <Health recordsPragmatic cluster randomised controlled trialCluster randomised controlled trialImproving hypertension treatmentPrimary care settingBlood pressure control ratesBlood pressureProportion of visitsProportion of participantsRandomised controlled trialsSystolic blood pressure <Control groupInjurious fallsRelated visitsCare settingsDiastolic blood pressure <Follow-upMyalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection
Unger E, Lin J, Wisk L, Yu H, L’Hommedieu M, Lavretsky H, Montoy J, Gottlieb M, Rising K, Gentile N, Santangelo M, Venkatesh A, Rodriguez R, Hill M, Geyer R, Kean E, Saydah S, McDonald S, Huebinger R, Idris A, Dorney J, Hota B, Spatz E, Stephens K, Weinstein R, Elmore J, Koo K, Derden A, Gatling K, Guzman D, Yang G, Kaadan A, Hassaballa M, Jerger R, Ahmed Z, Choi M, Pavlopoulos A, Kesari A, Gaylord C, Gomez C, Lomas E, Boliboun P, Patel K, Malicki C, Lin Z, Li S, Ebna Mannan I, Yang Z, Liu M, Ulrich A, Kinsman J, Pierce S, Puente X, Salah W, Nichol G, Anderson J, Schiffgens M, Morse D, Adams K, Stober T, Maat Z, O’Laughlin K, Willis M, Zhang Z, Chang G, Lyon V, Klabbers R, Ruiz L, Malone K, Park J, Renzi N, Watts P, Kelly M, Schaeffer K, Grau D, Cheng D, Shutty C, Charlton A, Shughart L, Shughart H, Amadio G, Miao J, Hannikainen P, Chandler C, Diaz Roldan K, Eguchi M, Moreno R, Wang R, Kemball R, Chan V, Lara Chavez C, Wong A, Arreguin M, Kane A, Nikonowicz P, Sapp S, Gallegos D, Martin K, Plumb I, Hall A, Briggs-Hagen M. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection. JAMA Network Open 2024, 7: e2423555. PMID: 39046739, PMCID: PMC11270135, DOI: 10.1001/jamanetworkopen.2024.23555.Peer-Reviewed Original ResearchConceptsProportion of participantsMyalgic encephalomyelitis/chronic fatigue syndromeME/CFS symptomsFatigue syndromeIndex illnessMonths of follow-upCohort studySARS-CoV-2 infectionSelf-reported symptomsLongitudinal cohort studySARS-CoV-2 test resultsSurvey completion rateFollow-up surveyFollow-upProspective cohort studyCognitive problemsCOVID-19 positivitySARS-CoV-2SARS-CoV-2 testingTime of illnessMain OutcomesAdjusted analysesSocietal burdenCompletion ratesAcute SARS-CoV-2 infectionTenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial
Xiong Y, Wang L, Pan Y, Wang M, Schwamm L, Duan C, Campbell B, Li S, Hao M, Wu N, Cao Z, Wu S, Li Z, Wang Y. Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial. Stroke And Vascular Neurology 2024, 10: 112-119. PMID: 38858097, PMCID: PMC11877429, DOI: 10.1136/svn-2023-003048.Peer-Reviewed Original ResearchSymptomatic intracranial haemorrhageAcute ischaemic strokeModified Rankin ScaleElderly patientsPost hoc analysisAlteplase groupTenecteplase groupHoc analysisAlternative to alteplaseModified Rankin scale 0Ischaemic strokeRisk-benefit profileNon-inferiority clinical trialBenefit-risk profileEfficacy outcomesProportion of participantsReperfusion therapyIntracranial haemorrhageClinical trialsRankin ScaleSymptom onsetTenecteplaseAlteplaseIntravenous thrombolyticsSafety outcomesSodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia REALIZE-K Design and Baseline Characteristics
Kosiborod M, Cherney D, Connelly K, Desai A, Guimarães P, Kuthi L, Lala A, Madrini V, Merkely B, Villota J, Squire I, Testani J, Vaclavik J, Verma S, Wranicz J, Dahl M, Eudicone J, Friberg L, Petrie M. Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia REALIZE-K Design and Baseline Characteristics. JACC Heart Failure 2024, 12: 1707-1716. PMID: 38878009, DOI: 10.1016/j.jchf.2024.05.003.Peer-Reviewed Original ResearchMineralocorticoid receptor antagonistsSodium zirconium cyclosilicateZirconium cyclosilicateBaseline characteristicsOpen-label run-inN-terminal pro B-type natriuretic peptideMineralocorticoid receptor antagonist useRun-inPro B-type natriuretic peptideB-type natriuretic peptidePlacebo-controlled trialRisk of hyperkalemiaReduced ejection fractionPrimary composite endpointDouble-blindEjection fractionReceptor antagonistLowered potassiumOptimal therapyNatriuretic peptideIncident hyperkalemiaProportion of participantsTherapy useHFrEFComposite endpointWillingness to take less medication for type 2 diabetes among older patients: The Diabetes & Aging Study
Haider S, Parker M, Huang E, Grant R, Moffet H, Laiteerapong N, Jain R, Liu J, Lipska K, Karter A. Willingness to take less medication for type 2 diabetes among older patients: The Diabetes & Aging Study. Journal Of The American Geriatrics Society 2024, 72: 1985-1994. PMID: 38471959, PMCID: PMC11226366, DOI: 10.1111/jgs.18870.Peer-Reviewed Original ResearchAmerican Diabetes AssociationKaiser Permanente Northern California Diabetes RegistryOlder patientsDuration of diabetesPatient-clinician relationshipDe-intensify treatmentHealth status categoriesProportion of willingnessProportion of participantsGlucose-lowering medicationsDiabetes RegistrySurvey responses to questionsResponses to questionsOlder adultsHealth statusType 2 diabetesClinical guidelinesDiabetes medicationsStatus categoriesDiabetes AssociationOlder individualsAging StudyTreatment de-intensificationRandom sampleSurvey responsesDigital health interventions for suicide prevention among LGBTQ: A narrative review
Paudel K, Gautam K, Bhandari P, Shah S, Wickersham J, Acharya B, Sapkota S, Adhikari S, Baral P, Shrestha A, Shrestha R. Digital health interventions for suicide prevention among LGBTQ: A narrative review. Health Prospect 2024, 23: 1-10. PMID: 38645301, PMCID: PMC11027749, DOI: 10.3126/hprospect.v23i1.62795.Peer-Reviewed Original ResearchDigital health interventionsMcGill Mixed Methods Appraisal ToolRandomized controlled trialsDigital interventionsHealth interventionsSuicide preventionHealth servicesQualitative studyMixed Methods Appraisal ToolIncrease help-seeking behaviorImpact of digital interventionsConventional health servicesMethods Appraisal ToolHelp-seeking intentionsObtaining such servicesPre-posttest designHelp-seeking behaviorSuicidal thoughtsMiddle-income countriesDigital-based interventionsProportion of participantsPowered randomized controlled trialsNon-overlapping studiesLGBTQ communityPerceived stigmaSevere Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey
Sherr J, Laffel L, Liu J, Wolf W, Bispham J, Chapman K, Finan D, Titievsky L, Liu T, Hagan K, Gaglia J, Chandarana K, Bergenstal R, Pettus J. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey. Diabetes Care 2024, 47: 941-947. PMID: 38295397, DOI: 10.2337/dc23-1765.Peer-Reviewed Original ResearchImpaired awareness of hypoglycemiaSevere hypoglycemic eventsType 1 diabetesGlycemic targetsContinuous glucose monitoringInsulin delivery modalityDiabetes technologyImproved treatment strategiesAwareness of hypoglycemiaImpaired awarenessU.S. RESEARCH DESIGNAdvanced diabetes technologiesProportion of participantsCross-sectional surveySubgroup analysisSevere hypoglycemiaTreatment strategiesAutomated insulin deliveryImpact of continuous glucose monitoringGlycemic metricsHypoglycemic eventsObservational studyProportion of peopleResearch designInsulin deliveryOutcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
Li S, Wangqin R, Pan Y, Jin A, Li H, Schwamm L, Fisher M, Campbell B, Parsons M, Wang Z, Dai H, Li D, Li R, Wang J, Wang D, Wang Y, Zhao X, Li Z, Zheng H, Xiong Y, Meng X, Wang Y. Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial. Stroke And Vascular Neurology 2024, 9: svn-2023-002694. PMID: 38296586, PMCID: PMC11791627, DOI: 10.1136/svn-2023-002694.Peer-Reviewed Original ResearchOnset to treatment timeAcute ischaemic strokeEfficacy outcomesSubgroup analysisPost hoc subgroup analysisModified Rankin Scale scoreIschaemic strokeExcellent functional outcomeAcute ischaemic stroke patientsBenefit of intravenous alteplasePooled risk differenceRankin Scale scoreSymptomatic intracranial haemorrhageControlled clinical trialsStroke onset to treatment timePost hoc analysisNon-inferiority trialOpen-labelTenecteplase groupIntravenous tenecteplaseNon-inferior to alteplaseProportion of participantsReperfusion therapyIntracranial haemorrhageIntravenous alteplase
2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.Peer-Reviewed Original ResearchConceptsApparent treatment-resistant hypertensionBaseline blood pressureTreatment-resistant hypertensionVentricular ejection fractionEjection fractionNonresistant hypertensionPrimary outcomeHeart failureBP categoriesHigher left ventricular ejection fractionSystolic baseline blood pressureLeft ventricular ejection fractionRelative treatment benefitSerious adverse eventsKey secondary outcomesRisk of hypotensionWorse kidney functionHigh-risk populationProportion of participantsBaseline BP categoriesGreater absolute reductionCardiometabolic comorbiditiesHypertension groupVascular eventsAdverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply